Praxsyn Corporation (PXYN) 0.0076 $PXYN Technical Data

New Post Public Reply Private Reply Replies (0) Message Board

Apr 7, 2016 at 3:42 AM

Praxsyn Corporation (PXYN) 0.0076 $PXYN

Technical Data and the Price Movement -- Analyst Review of Praxsyn, Baristas Coffee Company, Soligenix and Acacia Diversified Holdings
ACCESSWIRE - Mon Feb 01, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Praxsyn Corp. (OTC: PXYN), Baristas Coffee Company Inc. (OTC: BCCI), Soligenix Inc. (OTC: SNGX) and Acacia Diversified Holdings Inc. (OTC: ACCA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Market Influences That Drive Equities Forward - New Research on American Green, Praxsyn, Norsk Hydro and Soligenix
ACCESSWIRE - Thu Jan 21, 8:03AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: American Green Inc. (OTC: ERBB), Praxsyn Corp. (OTC: PXYN), Norsk Hydro ASA (OTC: NHYDY) and Soligenix Inc. (OTC: SNGX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Praxsyn Corporation Launches New Website
GlobeNewswire - Mon Sep 21, 7:04PM CDT
Praxsyn Corporation (OTCQB

XYN), a diversified holding company that finds alternative solutions to fit the needs and goals of their strategic relationships, is pleased to announce the launch of its new website www.praxsyn.com. According to Edward Kurtz, CEO of Praxsyn, the new website is aimed at highlighting the company's strategic vision for growth and expansion over the next few years, and beyond.

Praxsyn Corporation's Form 10-Q Filed for Second Quarter 2015
GlobeNewswire - Wed Aug 19, 4:35PM CDT
Praxsyn Corporation (OTCQB

XYN) today announced that it has filed its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2015. Full details of the financial results, as well as Management's Discussion & Analysis, can be found in the Form 10-Q on file with the Securities and Exchange Commission.

Praxsyn Corporation Announces New Chief Financial Officer
GlobeNewswire - Mon Jul 27, 9:10AM CDT
Praxsyn Corporation's (OTCQB

XYN) today announced that Justin Cary, 33, has been appointed by the Board of Directors as the company's Chief Financial Officer (CFO) effective immediately.

Praxsyn Corporation Growth Requires Expansion Into New Space
GlobeNewswire - Thu Jul 16, 9:04AM CDT
Praxsyn Corporation (OTCQB

XYN) is pleased to announce that it has finalized a lease on a new building for its pharmacy lab and billing services with expansion efforts now underway. The new space will allow Praxsyn's wholly owned subsidiary, Mesa Pharmacy (Mesa), a medication and service provider for medical practitioners, to significantly increase the size of its pharmacy lab, providing capacity for new equipment, a more diverse list of offered medications, and to continue the growth of its pharmacy staff. The expansion will also provide additional space for another wholly-owned subsidiary, NexGen Med Solutions (NexGen), a billing and collections company.

Praxsyn's 2015 Anticipated Business Strategies
GlobeNewswire - Mon Jun 08, 12:03PM CDT
Praxsyn Corporation's (OTCQB

XYN) anticipated business plan for 2015 is to acquire a sister subsidiary retail community pharmacy and to purchase additional pharmacies. Mesa is also in the early stages of developing a program to supply medications and products to diabetic patients and anticipates the commencement of filling prescriptions by the end of the third quarter of 2015.

Praxsyn Announces New Business Associate Agreement With Products for Doctors
GlobeNewswire - Tue Apr 14, 8:15AM CDT
Praxsyn Corporation's (OTCQB

XYN) wholly owned subsidiary, Mesa Pharmacy Inc. (Mesa), entered into a Business Associate Agreement with Products for Doctors for marketing and other services on January 23, 2015. The non-exclusive agreement between Products for Doctors and Mesa facilitates the marketing of Mesa's products to medical providers throughout California.

Praxsyn Announces New Pharmacist in Charge for Mesa Pharmacy
GlobeNewswire - Mon Mar 09, 1:55PM CDT
Praxsyn Corporation's (OTCQB

XYN) wholly owned subsidiary, Mesa Pharmacy Inc. (Mesa), announced today that, as of February 12, 2015, Dr. Amy Lee (Hawkins) Summers, Pharm, D., has joined the company as its new pharmacist in charge (PIC) and director of pharmacy.

Praxsyn Corporation Announces Mesa Pharmacy Has Commenced Processing of PPO Prescriptions
GlobeNewswire - Thu Dec 18, 11:56AM CST
Praxsyn Corporation (OTCQB

XYN), the parent company of Mesa Pharmacy, today announced that it has begun to process PPO prescriptions. Mesa Pharmacy is dedicated to providing medical practitioners with medications for patients through this move into the PPO network with its new and advanced products.

Praxsyn Corporation Now Licensed to Dispense Medication in 22 States
GlobeNewswire - Fri Dec 12, 9:02AM CST
Praxsyn Corporation (OTCQB

XYN), today announced that its wholly owned subsidiary, Mesa Pharmacy Inc., a medication and service provider for medical practitioners, has continued to make progress towards its goal of dispensing its customized medications nationwide. "We believe in our products and we are excited to help patients nationwide," said Andrew Do, Chief Pharmacist, Mesa Pharmacy. The company is now licensed to dispense its medications in the following 22 states:

Praxsyn Corporation Announces Change of Domicile From Illinois to Nevada and Appointment of New Board Members
GlobeNewswire - Wed Nov 05, 8:30AM CST
Praxsyn Corporation (OTCQB

XYN) announced today that the majority of its shareholders have voted to change domiciles from the state of Illinois to Nevada. Praxsyn Corporation shareholders entitled to vote authorized the change of domicile via their majority written consent due to: a) Nevada's favorable corporate laws; b) lower corporate income taxes; and c) easily accessible corporate filings through the Nevada Secretary of State's web portal.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...